Nichole Coleman, Ph.D.
|2014||Chemistry||University of California, Davis, Davis, CA|
Area:Organic Chemistry, Medicine and Surgery
Mean distance: (not calculated yet)
ParentsSign in to add mentor
ChildrenSign in to add trainee
CollaboratorsSign in to add collaborator
BETA: Related publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Oliván-Viguera A, Valero MS, Pinilla E, et al. (2016) Vascular reactivity profile of novel KC a 3.1-selective positive-gating modulators in the coronary vascular bed. Basic & Clinical Pharmacology & Toxicology|
|OlivÃ¡n-Viguera A, Valero MS, Coleman N, et al. (2015) A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo. Molecular Pharmacology. 87: 338-48|
|Coleman N, Nguyen HM, Cao Z, et al. (2015) The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 234-49|
|Coleman N, Brown BM, OlivÃ¡n-Viguera A, et al. (2014) New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Molecular Pharmacology. 86: 342-57|
|Lam J, Coleman N, Garing AL, et al. (2013) The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opinion On Therapeutic Targets. 17: 1203-20|
|Strøbæk D, Brown DT, Jenkins DP, et al. (2013) NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. British Journal of Pharmacology. 168: 432-44|
|Bodendiek SB, Rubinos C, Trelles MP, et al. (2012) Triarylmethanes, a new class of cx50 inhibitors. Frontiers in Pharmacology. 3: 106|